EpiVax
EpiVax, Inc. is a biotechnology company focused on the development of vaccines and immunotherapies using its proprietary computational immunology tools. The company, founded in 1998, is headquartered in Providence, Rhode Island, United States. EpiVax's technology platform leverages in silico (computer-based) tools to predict the immunogenicity of proteins, which is crucial for the development of effective vaccines and therapeutic proteins.
Overview[edit | edit source]
EpiVax's approach to vaccine and immunotherapy development is centered around its in silico immunogenicity prediction tools, which include the Immunoinformatics platform. This platform utilizes algorithms and databases to predict how the human immune system will respond to new proteins. By identifying potential immunogenic or tolerogenic regions within proteins, EpiVax aims to design vaccines and biologics that are more effective and less likely to cause adverse immune reactions.
Technology and Applications[edit | edit source]
The core of EpiVax's technology is the application of Immunoinformatics, which combines bioinformatics and immunology to predict the immunogenic potential of proteins. This technology has applications in several areas, including:
- Vaccine Design: EpiVax's tools can identify epitopes (parts of antigens that are recognized by the immune system) that are most likely to elicit a strong and protective immune response, aiding in the design of vaccines against infectious diseases.
- Autoimmune Disease Therapies: By identifying and modifying immunogenic regions in therapeutic proteins, EpiVax aims to reduce the risk of autoimmune responses, making treatments safer for patients with autoimmune diseases.
- Cancer Immunotherapy: The company's technology also has potential applications in cancer immunotherapy, where the goal is to design treatments that can effectively target and eliminate cancer cells by enhancing the patient's immune response against tumor-specific antigens.
Research and Development[edit | edit source]
EpiVax is involved in research and development activities across various therapeutic areas. The company collaborates with academic institutions, government agencies, and other biotechnology and pharmaceutical companies to advance its research projects and develop its technology platform.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD